Primary Job Title CEO Primary Organization 
eXIthera Pharmaceuticals
Location United States, North America Gender Male
Dr. Hayward has held previous positions within both large pharmaceutical companies (GSK and Pfizer) and biotechnology companies (Alkermes, Praecis, Daiamed, and Hydra Biosciences). He has over 30 years experience in discovery, preclinical research and development, and has successfully filed 7 INDs and product registrations of 2 new chemical
entities. Prior to co-founding and being the President and Chief Executive Officer at eXIthera Pharmaceuticals in August 2012, Dr. Hayward was Vice President of Pharmacology & Toxicology at Hydra Biosciences. At Hydra Biosciences, Dr. Hayward played a key role in the identification and selection of ion channels as potential therapeutic targets, the execution of preclinical studies, and the subsequent nomination of small molecules as development candidates for internal projects and external collaborations (Cubist Pharmaceuticals, Pfizer and Zalicus). Therapeutic targets investigated include pain, inflammation, asthma, anxiety, and bladder function. With colleagues at Cubist Pharmaceuticals, he identified a potent, selective and orally active TRPA1 inhibitor as a potential novel painkiller. The development candidate (CB-189,625) has recently successfully completed Phase 1 clinical trials. Dr. Hayward received his B.Sc. (Hons) degree from the University of London and M.Phil. & Ph.D. degrees in Pharmacology from the University of Cambridge, UK. Dr. Hayward has published over 80 scientific papers and abstracts and is an author on 6 patents and 7 patent applications.
